Lista de obras -

17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer

artículo científico publicado en 2006

17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

artículo científico publicado en 2010

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer ⬇️

artículo científico publicado el 6 de julio de 2012

A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer

artículo científico publicado en 2007

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit ⬇️

artículo científico publicado el 15 de diciembre de 2012

Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.

artículo científico publicado en 2005

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification

artículo científico publicado en 2005

Akt kinases in breast cancer and the results of adjuvant therapy

artículo científico publicado en 2003

Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

artículo científico publicado en 2009

Amplification of HSD17B1 and ERBB2 in primary breast cancer

artículo científico publicado en 2003

Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer

artículo científico publicado en 2007

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

artículo científico publicado en 2016

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

scientific article published on 08 August 2019

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

artículo científico publicado en 2006

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence ⬇️

artículo científico publicado el 11 de junio de 2013

C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

artículo científico publicado en 2014

Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer ⬇️

artículo científico publicado el 16 de octubre de 2010

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.

artículo científico publicado en 2006

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

artículo científico publicado en 2014

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

artículo científico publicado en 2015

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

artículo científico publicado en 2010

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer

artículo científico publicado en 2017

Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer

artículo científico publicado en 2010

Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome

scientific article published on 24 April 2007

Expression of COX-2 and steroid converting enzymes in breast cancer

scientific article published on 01 August 2006

Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: A long-term follow-up of the SweBCG91-RT randomised trial

scientific article published on 18 September 2020

Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy

artículo científico publicado en 2008

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

artículo científico publicado en 2005

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

artículo científico publicado en 2012

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information

artículo científico publicado en 2007

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer

scientific article published on 14 September 2016

High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1 ⬇️

artículo científico publicado el 11 de julio de 2011

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

artículo científico publicado en 2016

IP6K2 predicts favorable clinical outcome of primary breast cancer

artículo científico publicado en 2021

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen ⬇️

artículo científico publicado el 19 de octubre de 2010

Improved DNA flow cytometric, DNA ploidy, and S‐phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines ⬇️

artículo científico publicado el 1 de noviembre de 2003

Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy

artículo científico publicado en 2009

Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer

artículo científico publicado en 2007

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer

artículo científico publicado en 2014

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance

artículo científico publicado en 2015

Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer

artículo científico publicado en 2012

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

artículo científico publicado en 2020

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer

article published in 2018

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer

artículo científico publicado en 2009

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

artículo científico publicado en 2007

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

artículo científico publicado en 2010

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

artículo científico publicado en 2016

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

artículo científico publicado en 2015

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.

artículo científico publicado en 2017

Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

artículo científico publicado en 2009

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

artículo científico publicado en 2013

Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis

artículo científico publicado en 2015

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

artículo científico publicado en 2017

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

artículo científico publicado en 2005

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

artículo científico publicado en 2015

Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer

artículo científico publicado en 2011

Sulfotransferase1A1 and risk of postmenopausal breast cancer

scientific article published on 01 May 2005

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

artículo científico publicado en 2017

The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer

artículo científico publicado en 2013

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

artículo científico publicado en 2013

The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval – prognostic implications? ⬇️

artículo científico publicado el 23 de enero de 2013

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer

artículo científico publicado en 2017

The role of microRNA-200 in progression of human colorectal and breast cancer

artículo científico publicado en 2013

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

artículo científico publicado en 2021

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast canc

artículo científico publicado en 2005

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial

artículo científico publicado en 2016

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up

artículo científico publicado en 2005

VAV3 mediates resistance to breast cancer endocrine therapy.

artículo científico publicado en 2014

p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients

artículo científico publicado en 2010

p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients

artículo científico publicado en 2006

Lista de obras de

17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer

17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer ⬇️

A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit ⬇️

Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification

Akt kinases in breast cancer and the results of adjuvant therapy

Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

Amplification of HSD17B1 and ERBB2 in primary breast cancer

Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence ⬇️

C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer ⬇️

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer

Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer

Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome

Expression of COX-2 and steroid converting enzymes in breast cancer

Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: A long-term follow-up of the SweBCG91-RT randomised trial

Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer

High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1 ⬇️

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

IP6K2 predicts favorable clinical outcome of primary breast cancer

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen ⬇️

Improved DNA flow cytometric, DNA ploidy, and S‐phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines ⬇️

Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy

Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance

Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.

Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer

Sulfotransferase1A1 and risk of postmenopausal breast cancer

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval – prognostic implications? ⬇️

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer

The role of microRNA-200 in progression of human colorectal and breast cancer

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast canc

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up

VAV3 mediates resistance to breast cancer endocrine therapy.

p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients

p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients